As of November 6, 2026, Metagenomi Therapeutics, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 10, 2026 (Form 8-K, June 10, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Metagenomi Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Metagenomi Therapeutics, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-10. Every row below is cited to the filing it comes from, and this page adds each new change as Metagenomi Therapeutics, Inc. files it.
Also on the record for Metagenomi Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| September 10, 2026 | Stake report, Schedule 13G, by Thomas Brian C. | 7.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Metagenomi Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Watch Metagenomi Therapeutics, Inc.
Get an email when Metagenomi Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Metagenomi Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Metagenomi Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Metagenomi Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
2 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-10 | Reported | not named in the filing | 8-K, 2026-06-10 |
New leaders reset buying decisions — get the Full Report on Metagenomi Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Metagenomi Therapeutics, Inc., with the record behind each one.
Find candidates like senior executive at Metagenomi Therapeutics, Inc.Every change, in the filing's words
Reported
On June 9, 2026, Brian C. Thomas, Ph.D. informed the board of directors (the "Board") of Metagenomi Therapeutics, Inc. (the "Company") of his resignation from his position as a member of the Board, effective as of June 9, 2026.
- Dr. Thomas' resignation from the Board was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- The Company extends its deepest gratitude to Dr. Thomas for his distinguished service to the Board and lasting contributions to the Company.
Tools for this story
Each opens in a new tab, filled in for Metagenomi Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.